PTN
Palatin Technologies, Inc. Common StockstockNASDAQ
palatin technologies, inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the united states. the company's lead product is vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. it is also developing oral pl8177, a selective melanocortin receptor (mcr) 1 agonist peptide that has completed phase i clinical trial for the treatment of inflammatory bowel diseases; and systemic pl8177, which has completed phase i clinical trial for treating non-infectious uveitis and covid-19. in addition, the company engages in the development of pl9643, a peptide melanocortin agonist active at multiple mcrs, including mc1r and mc5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. further, it is developing pl3994, a natriuretic peptide receptor (npr)-a agonist and sy
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 6.23 | 2026-11-13 | -21.35% | -1.894 |
| 1M | 5.52 | 2026-10-20 | -11.23% | 2.755 |
| 3M | 10.20 | 2026-08-20 | -51.96% | 2.423 |
| 6M | 14.59 | 2026-05-20 | -66.42% | 1.108 |
| 1Y | 14.49 | 2025-11-20 | -66.18% | 0.887 |
| 2Y | 0.91 | 2024-11-20 | +435.99% | — |
| 5Y | 9.00 | 2021-11-19 | -45.57% | 0.165 |
Palatin Technologies, Inc. Common Stock (NASDAQ:PTN) stock price today is $4.90, and today's volume is 13,886. PTN is down 4.854% today. The 30 day average volume is 37,975. PTN market cap is $8.73M with 1.78M shares outstanding.
